Healthcare provider profile · identity verified

Gary Montsdeoca, M.D.

Rheumatology · SEBRING, FL · NPI 1508899402

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	355	57
Atorvastatin Calcium	Atorvastatin Calcium	331	89
Furosemide	Furosemide	318	93
Trazodone Hcl	Trazodone Hcl	301	64
Gabapentin	Gabapentin	270	76
Divalproex Sodium	Divalproex Sodium	254	68
Potassium Chloride	Potassium Chloride	220	54
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	208	33
Levothyroxine Sodium	Levothyroxine Sodium	187	50
Amlodipine Besylate	Amlodipine Besylate	165	55
Sertraline Hcl	Sertraline Hcl	164	42
Prednisone	Prednisone	147	67
Metformin Hcl	Metformin Hcl	143	36
Losartan Potassium	Losartan Potassium	142	32
Metoprolol Tartrate	Metoprolol Tartrate	132	45
Tamsulosin Hcl	Tamsulosin Hcl	130	39
Levetiracetam	Levetiracetam	125	20
Lisinopril	Lisinopril	119	30
Clopidogrel	Clopidogrel Bisulfate	109	26
Mirtazapine	Mirtazapine	105	33
Spironolactone	Spironolactone	103	19
Donepezil Hcl	Donepezil Hcl	102	31
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	97	16
Memantine Hcl	Memantine Hcl	96	27
Tramadol Hcl	Tramadol Hcl	95	39
Methotrexate	Methotrexate Sodium	94	24
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	94	25
Quetiapine Fumarate	Quetiapine Fumarate	94	28
Pantoprazole Sodium	Pantoprazole Sodium	84	37
Alprazolam	Alprazolam	80	19
Azithromycin	Azithromycin	78	51
Lorazepam	Lorazepam	77	33
Meloxicam	Meloxicam	75	20
Lactulose	Lactulose	74	11
Rosuvastatin Calcium	Rosuvastatin Calcium	70	17
Pregabalin	Pregabalin	69	14
Hydralazine Hcl	Hydralazine Hcl	67	16
Carvedilol	Carvedilol	65	26
Glipizide	Glipizide	64	12
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	64	16
Zolpidem Tartrate	Zolpidem Tartrate	61	14
Metoprolol Succinate	Metoprolol Succinate	59	25
Latanoprost	Latanoprost	57	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	56	41
Midodrine Hcl	Midodrine Hcl	55	13
Ondansetron Hcl	Ondansetron Hcl	55	28
Glimepiride	Glimepiride	50	13
Montelukast Sodium	Montelukast Sodium	50	16
Hydrochlorothiazide	Hydrochlorothiazide	48	11
Januvia	Sitagliptin Phosphate	48	suppressed
Myrbetriq	Mirabegron	48	suppressed
Paroxetine Hcl	Paroxetine Hcl	48	16
Allopurinol	Allopurinol	45	13
Oxycodone Hcl	Oxycodone Hcl	45	13
Baclofen	Baclofen	43	suppressed
Bumetanide	Bumetanide	43	suppressed
Insulin Lispro	Insulin Lispro	43	20
Ropinirole Hcl	Ropinirole Hcl	42	suppressed
Celecoxib	Celecoxib	41	suppressed
Clonazepam	Clonazepam	41	suppressed
Topiramate	Topiramate	41	11
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Buspirone Hcl	Buspirone Hcl	39	14
Cephalexin	Cephalexin	38	25
Escitalopram Oxalate	Escitalopram Oxalate	36	13
Fiasp Flextouch	Insulin Aspart (Niacinamide)	36	suppressed
Nystatin	Nystatin	35	19
Jardiance	Empagliflozin	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Famotidine	Famotidine	32	12
Farxiga	Dapagliflozin Propanediol	32	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	32	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	29	21
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Risperidone	Risperidone	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	11
Digoxin	Digoxin	28	suppressed
Tradjenta	Linagliptin	27	suppressed
Amiodarone Hcl	Amiodarone Hcl	26	suppressed
Labetalol Hcl	Labetalol Hcl	26	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	19
Ziprasidone Hcl	Ziprasidone Hcl	26	suppressed
Haloperidol Lactate	Haloperidol Lactate	25	15
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Bethanechol Chloride	Bethanechol Chloride	24	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	24	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	24	11
Nifedipine Er	Nifedipine	24	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	23	suppressed
Diltiazem Hcl	Diltiazem Hcl	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	11
Lacosamide	Lacosamide	23	suppressed
Morphine Sulfate	Morphine Sulfate	23	11
Clonidine Hcl	Clonidine Hcl	22	suppressed
Ibuprofen	Ibuprofen	22	14
Methylprednisolone	Methylprednisolone	22	11
Simvastatin	Simvastatin	22	suppressed
Benztropine Mesylate	Benztropine Mesylate	21	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	21	suppressed
Ceftriaxone	Ceftriaxone Sodium	21	14
Lantus	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Metronidazole	Metronidazole	20	11
Temazepam	Temazepam	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Nuplazid	Pimavanserin Tartrate	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	11
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Morphine Sulfate Er	Morphine Sulfate	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Carbamazepine	Carbamazepine	17	suppressed
Fiasp	Insulin Aspart (Niacinamide)	17	suppressed
Haloperidol	Haloperidol	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Cefuroxime	Cefuroxime Axetil	16	suppressed
Folic Acid	Folic Acid	16	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	16	12
Methocarbamol	Methocarbamol	16	suppressed
Olanzapine	Olanzapine	16	suppressed
Solu-Medrol	Methylprednisolone Sod Succ/Pf	16	15
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Finasteride	Finasteride	14	suppressed
Glucagon Emergency Kit	Glucagon	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Omeprazole	Omeprazole	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Ranolazine Er	Ranolazine	14	suppressed
Rasuvo	Methotrexate/Pf	14	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	11
Torsemide	Torsemide	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Ozempic	Semaglutide	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	12	suppressed
Enbrel	Etanercept	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Primidone	Primidone	12	suppressed
Simponi	Golimumab	12	suppressed
Taltz Autoinjector	Ixekizumab	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	11	suppressed
Estradiol	Estradiol	11	suppressed
Humira Pen	Adalimumab	11	suppressed
Insulin Aspart Flexpen	Insulin Aspart	11	suppressed
Procrit	Epoetin Alfa	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Rinvoq	Upadacitinib	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error